Cutaneous toxicities to oncologic therapies and Interpretation of PD-L1 Immunohistochemistry Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology, Section of Dermatopathology and Translational and Molecular Pathology The University of Texas MD Anderson Cancer Center Executive Officer Translational Research Program The Alliance for Clinical Trials Cutaneous toxicities to oncologic therapies Commonly encountered cutaneous reactions to targeted therapy and immune checkpoint blockade Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology, Section of Dermatopathology and Translational and Molecular Pathology The University of Texas MD Anderson Cancer Center Executive Officer Translational Research Program The Alliance for Clinical Trials Significance of cutaneous toxicities to oncologic therapies • Indicator of response to therapy • Response to EGFR inhibitor therapy correlates with development and severity of skin rash • Response to immune checkpoint blockade correlates with pigmentary alteration • Mimicker of disease recurrence • Panniculitis can mimic disease recurrence • May require further procedure • SCC in the context of RAF inhibitors • May require alteration of therapy • Bullous pemphigoid in immune checkpoint blockade • Skin often exhibits toxicity early in the course of therapy and is accessible. 0 2 4 6 8 10 12 Toxicity Grade Time (weeks) Rash/pruritis Diarrhea/colitis Liver toxicity Common specific cutaneous toxicities to oncologic therapies • Anti-EGFR inhibitors • Papulopustular eruption • Immune checkpoint blockade (D D-CTLA4 and D-PD-1/D-PD-L1) • Lichenoid dermatitis • Bullous pemphigoid reaction • Granulomatous infiltrates • RAF inhibitor therapy • Squamous neoplasia • Panniculitis
27
Embed
Cutaneous toxicities to oncologic therapies Commonly … · 2018-05-14 · Cutaneous toxicities to oncologic therapies and Interpretation of PD-L1 Immunohistochemistry Michael T.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.